182 related articles for article (PubMed ID: 36394520)
21. Dual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth.
Grohar PJ; Segars LE; Yeung C; Pommier Y; D'Incalci M; Mendoza A; Helman LJ
Clin Cancer Res; 2014 Mar; 20(5):1190-203. PubMed ID: 24277455
[TBL] [Abstract][Full Text] [Related]
22. High-throughput tyrosine kinase activity profiling identifies FAK as a candidate therapeutic target in Ewing sarcoma.
Crompton BD; Carlton AL; Thorner AR; Christie AL; Du J; Calicchio ML; Rivera MN; Fleming MD; Kohl NE; Kung AL; Stegmaier K
Cancer Res; 2013 May; 73(9):2873-83. PubMed ID: 23536552
[TBL] [Abstract][Full Text] [Related]
23. Pathogenetic implications of early growth response 1 in Ewing sarcoma.
Noh BJ; Jung WW; Kim HS; Park YK
Pathology; 2019 Oct; 51(6):605-609. PubMed ID: 31466866
[TBL] [Abstract][Full Text] [Related]
24. Combining PARP-1 inhibition and radiation in Ewing sarcoma results in lethal DNA damage.
Lee HJ; Yoon C; Schmidt B; Park DJ; Zhang AY; Erkizan HV; Toretsky JA; Kirsch DG; Yoon SS
Mol Cancer Ther; 2013 Nov; 12(11):2591-600. PubMed ID: 23966622
[TBL] [Abstract][Full Text] [Related]
25. mTORC1/2 and Protein Translation Regulate Levels of CHK1 and the Sensitivity to CHK1 Inhibitors in Ewing Sarcoma Cells.
Koppenhafer SL; Goss KL; Terry WW; Gordon DJ
Mol Cancer Ther; 2018 Dec; 17(12):2676-2688. PubMed ID: 30282812
[TBL] [Abstract][Full Text] [Related]
26. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma.
Kennedy AL; Vallurupalli M; Chen L; Crompton B; Cowley G; Vazquez F; Weir BA; Tsherniak A; Parasuraman S; Kim S; Alexe G; Stegmaier K
Oncotarget; 2015 Oct; 6(30):30178-93. PubMed ID: 26337082
[TBL] [Abstract][Full Text] [Related]
27. IGF-1R/MDM2 relationship confers enhanced sensitivity to RITA in Ewing sarcoma cells.
Di Conza G; Buttarelli M; Monti O; Pellegrino M; Mancini F; Pontecorvi A; Scotlandi K; Moretti F
Mol Cancer Ther; 2012 Jun; 11(6):1247-56. PubMed ID: 22461661
[TBL] [Abstract][Full Text] [Related]
28. PTEN deficiency mediates a reciprocal response to IGFI and mTOR inhibition.
Patel M; Gomez NC; McFadden AW; Moats-Staats BM; Wu S; Rojas A; Sapp T; Simon JM; Smith SV; Kaiser-Rogers K; Davis IJ
Mol Cancer Res; 2014 Nov; 12(11):1610-20. PubMed ID: 24994750
[TBL] [Abstract][Full Text] [Related]
29. Pre-clinical efficacy of PU-H71, a novel HSP90 inhibitor, alone and in combination with bortezomib in Ewing sarcoma.
Ambati SR; Lopes EC; Kosugi K; Mony U; Zehir A; Shah SK; Taldone T; Moreira AL; Meyers PA; Chiosis G; Moore MA
Mol Oncol; 2014 Mar; 8(2):323-36. PubMed ID: 24388362
[TBL] [Abstract][Full Text] [Related]
30. Stable interference of EWS-FLI1 in an Ewing sarcoma cell line impairs IGF-1/IGF-1R signalling and reveals TOPK as a new target.
Herrero-Martín D; Osuna D; Ordóñez JL; Sevillano V; Martins AS; Mackintosh C; Campos M; Madoz-Gúrpide J; Otero-Motta AP; Caballero G; Amaral AT; Wai DH; Braun Y; Eisenacher M; Schaefer KL; Poremba C; de Alava E
Br J Cancer; 2009 Jul; 101(1):80-90. PubMed ID: 19491900
[TBL] [Abstract][Full Text] [Related]
31. Germline PTPRD mutations in Ewing sarcoma: biologic and clinical implications.
Jiang Y; Janku F; Subbiah V; Angelo LS; Naing A; Anderson PM; Herzog CE; Fu S; Benjamin RS; Kurzrock R
Oncotarget; 2013 Jun; 4(6):884-9. PubMed ID: 23800680
[TBL] [Abstract][Full Text] [Related]
32. A pivotal role for heat shock protein 90 in Ewing sarcoma resistance to anti-insulin-like growth factor 1 receptor treatment: in vitro and in vivo study.
Martins AS; Ordoñez JL; García-Sánchez A; Herrero D; Sevillano V; Osuna D; Mackintosh C; Caballero G; Otero AP; Poremba C; Madoz-Gúrpide J; de Alava E
Cancer Res; 2008 Aug; 68(15):6260-70. PubMed ID: 18676850
[TBL] [Abstract][Full Text] [Related]
33. TAE226, a dual inhibitor of focal adhesion kinase and insulin-like growth factor-I receptor, is effective for Ewing sarcoma.
Moritake H; Saito Y; Sawa D; Sameshima N; Yamada A; Kinoshita M; Kamimura S; Konomoto T; Nunoi H
Cancer Med; 2019 Dec; 8(18):7809-7821. PubMed ID: 31692287
[TBL] [Abstract][Full Text] [Related]
34. Targeting EYA3 in Ewing Sarcoma Retards Tumor Growth and Angiogenesis.
Wang Y; Pandey RN; Roychoudhury K; Milewski D; Kalin TV; Szabo S; Pressey JG; Hegde RS
Mol Cancer Ther; 2021 May; 20(5):803-815. PubMed ID: 33649104
[No Abstract] [Full Text] [Related]
35. Eltrombopag inhibits the proliferation of Ewing sarcoma cells via iron chelation and impaired DNA replication.
Waters T; Goss KL; Koppenhafer SL; Terry WW; Gordon DJ
BMC Cancer; 2020 Nov; 20(1):1171. PubMed ID: 33256675
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic Targeting of KDM1A/LSD1 in Ewing Sarcoma with SP-2509 Engages the Endoplasmic Reticulum Stress Response.
Pishas KI; Drenberg CD; Taslim C; Theisen ER; Johnson KM; Saund RS; Pop IL; Crompton BD; Lawlor ER; Tirode F; Mora J; Delattre O; Beckerle MC; Callen DF; Sharma S; Lessnick SL
Mol Cancer Ther; 2018 Sep; 17(9):1902-1916. PubMed ID: 29997151
[TBL] [Abstract][Full Text] [Related]
37. Gene expression signature based screening identifies ribonucleotide reductase as a candidate therapeutic target in Ewing sarcoma.
Goss KL; Gordon DJ
Oncotarget; 2016 Sep; 7(39):63003-63019. PubMed ID: 27557498
[TBL] [Abstract][Full Text] [Related]
38. Targeting IGF Perturbs Global Replication through Ribonucleotide Reductase Dysfunction.
Rieunier G; Wu X; Harris LE; Mills JV; Nandakumar A; Colling L; Seraia E; Hatch SB; Ebner DV; Folkes LK; Weyer-Czernilofsky U; Bogenrieder T; Ryan AJ; Macaulay VM
Cancer Res; 2021 Apr; 81(8):2128-2141. PubMed ID: 33509941
[TBL] [Abstract][Full Text] [Related]
39. Gene expression of the IGF pathway family distinguishes subsets of gastrointestinal stromal tumors wild type for KIT and PDGFRA.
Beadling C; Patterson J; Justusson E; Nelson D; Pantaleo MA; Hornick JL; Chacón M; Corless CL; Heinrich MC
Cancer Med; 2013 Feb; 2(1):21-31. PubMed ID: 24133624
[TBL] [Abstract][Full Text] [Related]
40. Antitumor effects of β-elemene via targeting the phosphorylation of insulin receptor.
Wu D; Lv D; Zhang T; Guo L; Ma F; Zhang C; Lv G; Huang L
Endocr Relat Cancer; 2019 Feb; 26(2):187-199. PubMed ID: 30422809
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
